LifeArc offers a no-upfront-cost antibody humanisation service that has helped design five leading, market-approved drugs. We specialise in ‘tricky’ humanisation projects by applying our extensive experience and a collaborative model.
We offer a unique collaborative model where we take on the risk of the work to support teams who have the most promising candidate antibodies.
We have a success rate of more than 98% and have humanised more than 90 antibodies from a wide range of species, including mice, hamsters, rats, rabbits, chickens and camelids, producing therapeutic candidate molecules of various modalities including VHH, IgG, Fab and VH-Fc.
Our experience and track record in antibody design mean that your candidate antibody has the best chance of successfully progressing through to clinical trials, maximising the opportunity for your antibody to reach and benefit patients.
Find out more about humanising candidate antibodies with LifeArc
Collaborative model: humanisation & hand back
- No upfront payment – we take on the developmental risk so you don’t have to
- LifeArc receives a small royalty on sales after market approval has been secured
- We also consider other deal structures where appropriate
Get in touch with us today with your antibody humanisation requirements.